Nasdaq
$303.53▲ 0.15%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $6.08BShares out 20.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 10.6After-hours26.10.07 05:354Ownership#●●●
LIGAND PHARMACEUTICALS INC
Insider Andrew Reardon of Ligand Pharmaceuticals reported a change in beneficial ownership of securities as of October 2, 2026. This filing serves as a standard Form 4 disclosure regarding insider holdings.…more
$303.53+0.15%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.24After-hours26.09.25 06:224Ownership
LIGAND PHARMACEUTICALS INC
Executive Martine Zimmermann of Ligand Pharmaceuticals filed a Form 4 statement regarding changes in beneficial ownership of securities on September 22, 2026. This filing serves as a standard report on insider equity transactions.…more
$303.53+0.15%vs prev closeView filingShare - 9.24Pre-market26.09.24 20:158-KKey event
LIGAND PHARMACEUTICALS INC
Ligand Pharmaceuticals has entered into a financing agreement with AvenCell Therapeutics for up to $47 million. Ligand will invest $41 million in exchange for royalties on AvenCell's pipeline assets and an additional $6 million in Series C equity financing.…more
$303.53+0.15%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoAfter-hours26.10.23 05:01#●●●#●●●
Ligand Pharmaceuticals to Host Investor Day on December 8, 2026
Ligand Pharmaceuticals announced it will hold its annual Investor Day in New York on December 8, 2026. The event will feature presentations on the company's corporate strategy, financial outlook, and updates on its royalty portfolio and partner programs.…more
$303.53+0.15%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.15Pre-market26.10.15 20:00
●●●●●●●● ●●●●● ●●●●●●
Ligand Pharmaceuticals announced that it will release its third-quarter 2026 financial results on October 29, 2026. The company will host a conference call to discuss the results and provide a business update.…more
$303.53+0.15%vs prev close - 9.24Pre-market26.09.24 20:00
●●●●●●●● ●●●●● ●●●●●●
Ligand Pharmaceuticals has entered into a financing agreement of up to $47 million to support AvenCell's next-generation CAR-T therapy pipeline. The deal grants Ligand future royalty rights on AvenCell's net sales in exchange for the capital investment.…more
$303.53+0.15%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report